• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Clearside Biomedical Inc.

    3/4/25 5:20:57 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLSD alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 6)


    Clearside Biomedical, Inc.

    (Name of Issuer)


    Common Stock, $.001 Par Value

    (Title of Class of Securities)


    185063104

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    185063104


    1Names of Reporting Persons

    WHITMORE BRADFORD T
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,523,511.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,523,511.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,523,511.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.6 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Bradford T. Whitmore has shared voting power of 2,254,542 shares as the manager of Whitmore Holdings, LLC, which is the general partner of Grace Brothers, LP, the holder of the shares. Bradford T. Whitmore has shared voting power of 4,268,969 shares as the manager of Whitmore Holdings, LLC, the holder of the shares. Bradford T. Whitmore has shared dispositive power of 2,254,542 shares as the manager of Whitmore Holdings, LLC, which is the general partner of Grace Brothers, LP, the holder of the shares. Bradford T. Whitmore has shared dispositive power of 4,268,969 shares as the manager of Whitmore Holdings, LLC, the holder of the shares. Based on 75,843,504 shares of the Common Stock of the Issuer outstanding as of November 8, 2024, as reported in the Issuer's Form 10-Q for the quarter ended September 30, 2024, and filed with the U.S. Securities and Exchange Commission on November 12, 2024.


    SCHEDULE 13G

    CUSIP No.
    185063104


    1Names of Reporting Persons

    GRACE BROTHERS LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,254,542.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,254,542.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,254,542.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.9 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Based on 75,843,504 shares of the Common Stock of the Issuer outstanding as of November 8, 2024, as reported in the Issuer's Form 10-Q for the quarter ended September 30, 2024, and filed with the U.S. Securities and Exchange Commission on November 12, 2024.


    SCHEDULE 13G

    CUSIP No.
    185063104


    1Names of Reporting Persons

    Whitmore Holdings, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    TENNESSEE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    4,268,969.00
    6Shared Voting Power

    2,254,542.00
    7Sole Dispositive Power

    4,268,969.00
    8Shared Dispositive Power

    2,254,542.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,523,511.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.6 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Whitmore Holdings, LLC has shared voting power of 2,254,542 shares as the general partner of Grace Brothers, LP, the holder of the shares. Whitmore Holdings, LLC has shared dispositive power of 2,254,542 shares as the general partner of Grace Brothers, LP, the holder of the shares. Based on 75,843,504 shares of the Common Stock of the Issuer outstanding as of November 8, 2024, as reported in the Issuer's Form 10-Q for the quarter ended September 30, 2024, and filed with the U.S. Securities and Exchange Commission on November 12, 2024.


    SCHEDULE 13G

    CUSIP No.
    185063104


    1Names of Reporting Persons

    Bradford Whitmore Trust
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    TENNESSEE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,523,511.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,523,511.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,523,511.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.6 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Bradford Whitmore Trust has shared voting power of 2,254,542 shares as the sole member of Whitmore Holdings, LLC, which is the general partner of Grace Brothers, LP. Bradford Whitmore Trust has shared voting power of 4,268,969 shares as the sole member of Whitmore Holdings, LLC, the holder of the shares. Bradford Whitmore Trust has shared dispositive power of 2,254,542 shares as the sole member of Whitmore Holdings, LLC, which is the general partner of Grace Brothers, LP. Bradford Whitmore Trust has shares dispositive power of 4,268,969 shares as the sole member of Whitmore Holdings, LLC, the holder of the shares. Based on 75,843,504 shares of the Common Stock of the Issuer outstanding as of November 8, 2024, as reported in the Issuer's Form 10-Q for the quarter ended September 30, 2024, and filed with the U.S. Securities and Exchange Commission on November 12, 2024.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Clearside Biomedical, Inc.
    (b)Address of issuer's principal executive offices:

    900 NORTH POINT PARKWAY, SUITE 200, ALPHARETTA, GEORGIA, 30005.
    Item 2. 
    (a)Name of person filing:

    The statement is filed by Bradford T. Whitmore ("Whitmore"), Grace Brothers, LP ("Grace"), Whitmore Holdings, LLC ("WHLLC") and Bradford Whitmore Trust ("Whitmore Trust"). Whitmore is the sole trustee of Whitmore Trust and the manager of WHLLC. WHLLC is the general partner of Grace.
    (b)Address or principal business office or, if none, residence:

    The business address of Grace and Whitmore is 5215 Old Orchard Road, Ste 620, Skokie, IL 60077. The business address of WHLLC and Whitmore Trust is 4615 Churchwood Drive, Nashville, TN 37220.
    (c)Citizenship:

    Whitmore is a United States citizen. Grace is a Delaware limited partnership. WHLLC is a Tennessee limited liability company. Whitmore Trust is a trust formed under the laws of the State of Tennessee.
    (d)Title of class of securities:

    Common Stock, $.001 Par Value
    (e)CUSIP No.:

    185063104
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    6,523,511 shares Common Stock
    (b)Percent of class:

    8.6%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Grace has sole power to vote or to direct the vote for 2,254,542 shares. WHLLC has sole power to vote or to direct the vote for 4,268,969 shares.

     (ii) Shared power to vote or to direct the vote:

    Whitmore, WHLLC and Whitmore Trust have shared power to vote or direct the vote for 2,254,542 shares. Whitmore and Whitmore Trust have shared power to vote or direct the vote for 4,268,969 shares.

     (iii) Sole power to dispose or to direct the disposition of:

    Grace has sole power to dispose or to direct the disposition of 2,254,542 shares. WHLLC has sole power to dispose or to direct the disposition of 4,268,969 shares.

     (iv) Shared power to dispose or to direct the disposition of:

    Whitmore, WHLLC and Whitmore Trust have shared power to dispose or direct the disposition of 2,254,542 shares. Whitmore and Whitmore Trust have shared power to dispose or to direct the disposition of 4,268,969 shares.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    WHITMORE BRADFORD T
     
    Signature:Bradford T. Whitmore
    Name/Title:Bradford T. Whitmore
    Date:03/04/2025
     
    GRACE BROTHERS LP
     
    Signature:Whitmore Holdings, LLC
    Name/Title:General Partner
    Date:03/04/2025
     
    Whitmore Holdings, LLC
     
    Signature:Bradford T. Whitmore
    Name/Title:Manager
    Date:03/04/2025
     
    Bradford Whitmore Trust
     
    Signature:Bradford T. Whitmore
    Name/Title:Trustee
    Date:03/04/2025
    Get the next $CLSD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLSD

    DatePrice TargetRatingAnalyst
    8/21/2024$6.00Buy
    Chardan Capital Markets
    6/25/2024$5.00Outperform
    Oppenheimer
    3/11/2022$11.00 → $10.00Market Outperform
    JMP Securities
    12/15/2021$19.00 → $9.00Outperform
    Wedbush
    7/29/2021$10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CLSD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

      ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD) ("Clearside" or the "Company"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2025 financial results will be reported on Wednesday, May 14, 2025 after the close of the financial markets. The Company will not be hosting a conference call this quarter. Information about the Company's quarterly results, conference calls, webcasts and other investor information is available in the Investors section of the Company's website. About Clearside Biomedical, Inc. Clearsid

      5/8/25 7:05:00 AM ET
      $CLSD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference

      ALPHARETTA, Ga., May 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in a fireside chat at the Citizens Life Sciences Conference on Wednesday, May 7, 2025, at 1:00 p.m. ET. A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months. About Clearside Biomedical, Inc. Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the d

      5/1/25 7:05:00 AM ET
      $CLSD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

      ALPHARETTA, Ga., April 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, PharmD, JD, President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer and EVP, Head of Research & Development, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 12:45 p.m. ET. A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of

      4/1/25 7:05:00 AM ET
      $CLSD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLSD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for XIPERE issued to CLEARSIDE BIOMEDICAL, INC

      Submission status for CLEARSIDE BIOMEDICAL, INC's drug XIPERE (ORIG-1) with active ingredient TRIAMCINOLONE ACETONIDE has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form

      10/25/21 2:22:37 PM ET
      $CLSD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for SUSVIMO issued to CLEARSIDE BIOMEDICAL, INC

      Submission status for CLEARSIDE BIOMEDICAL, INC's drug SUSVIMO (ORIG-1) with active ingredient RANIBIZUMAB has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form

      10/25/21 2:07:19 PM ET
      $CLSD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLSD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Thorp Clay bought $13,800 worth of shares (15,000 units at $0.92), increasing direct ownership by 9% to 176,141 units (SEC Form 4)

      4 - Clearside Biomedical, Inc. (0001539029) (Issuer)

      2/24/25 5:52:59 PM ET
      $CLSD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Deignan Charles A.

      4 - Clearside Biomedical, Inc. (0001539029) (Issuer)

      1/10/25 4:30:10 PM ET
      $CLSD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Chong Ngai Hang Victor

      4 - Clearside Biomedical, Inc. (0001539029) (Issuer)

      1/10/25 4:30:07 PM ET
      $CLSD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLSD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Clearside Biomedical Inc. (Amendment)

      SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)

      11/1/23 4:04:12 PM ET
      $CLSD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Clearside Biomedical Inc. (Amendment)

      SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)

      2/14/23 10:29:32 AM ET
      $CLSD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Clearside Biomedical Inc. (Amendment)

      SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)

      2/13/23 12:19:46 PM ET
      $CLSD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLSD
    Financials

    Live finance-specific insights

    See more
    • Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

      ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD) ("Clearside" or the "Company"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2025 financial results will be reported on Wednesday, May 14, 2025 after the close of the financial markets. The Company will not be hosting a conference call this quarter. Information about the Company's quarterly results, conference calls, webcasts and other investor information is available in the Investors section of the Company's website. About Clearside Biomedical, Inc. Clearsid

      5/8/25 7:05:00 AM ET
      $CLSD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      - Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD - - Asia-Pacific Partner's New Drug Application for ARCATUS® (XIPERE®) for Uveitic Macular Edema Accepted for Regulatory Review in China - - Multiple Medical Meeting Presentations Highlight Potential Advantages and Key Differentiators of Suprachoroidal Drug Delivery Utilizing Clearside's SCS Microinjector® - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., March 27, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the

      3/27/25 4:05:00 PM ET
      $CLSD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025

      ALPHARETTA, Ga., March 12, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD) ("Clearside" or the "Company"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2024 financial results will be reported on Thursday, March 27, 2025 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call ca

      3/12/25 7:05:00 AM ET
      $CLSD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLSD
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Clearside Biomedical Inc.

      DEFA14A - Clearside Biomedical, Inc. (0001539029) (Filer)

      4/18/25 8:05:07 AM ET
      $CLSD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Clearside Biomedical Inc.

      DEF 14A - Clearside Biomedical, Inc. (0001539029) (Filer)

      4/18/25 8:00:19 AM ET
      $CLSD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Clearside Biomedical Inc.

      PRE 14A - Clearside Biomedical, Inc. (0001539029) (Filer)

      4/8/25 4:40:17 PM ET
      $CLSD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLSD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Thorp Clay bought $13,800 worth of shares (15,000 units at $0.92), increasing direct ownership by 9% to 176,141 units (SEC Form 4)

      4 - Clearside Biomedical, Inc. (0001539029) (Issuer)

      2/24/25 5:52:59 PM ET
      $CLSD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Chong Ngai Hang Victor bought $36,500 worth of shares (36,500 units at $1.00), increasing direct ownership by 57% to 100,000 units (SEC Form 4)

      4 - Clearside Biomedical, Inc. (0001539029) (Issuer)

      11/4/24 4:15:04 PM ET
      $CLSD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Chong Ngai Hang Victor bought $24,910 worth of shares (23,500 units at $1.06), increasing direct ownership by 59% to 63,500 units (SEC Form 4)

      4 - Clearside Biomedical, Inc. (0001539029) (Issuer)

      6/24/24 4:38:02 PM ET
      $CLSD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLSD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on Clearside Biomedical with a new price target

      Chardan Capital Markets initiated coverage of Clearside Biomedical with a rating of Buy and set a new price target of $6.00

      8/21/24 7:25:17 AM ET
      $CLSD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Clearside Biomedical with a new price target

      Oppenheimer initiated coverage of Clearside Biomedical with a rating of Outperform and set a new price target of $5.00

      6/25/24 7:30:23 AM ET
      $CLSD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities reiterated coverage on Clearside Biomedical with a new price target

      JMP Securities reiterated coverage of Clearside Biomedical with a rating of Market Outperform and set a new price target of $10.00 from $11.00 previously

      3/11/22 7:58:59 AM ET
      $CLSD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLSD
    Leadership Updates

    Live Leadership Updates

    See more
    • Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

      ALPHARETTA, Ga., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Tony Gibney as Chair of its Board of Directors, effective November 1, 2024. Mr. Gibney, who joined Clearside's Board as an independent director in April 2024, succeeds Clay Thorp, who will continue serving as a member of the Board. George Lasezkay, PharmD, JD, President and Chief Executive Officer, Clearside Biomedical, commented, "Tony is a highly respected member of our Board, bringing a wealth of strategic leadership experie

      11/4/24 7:05:00 AM ET
      $CLSD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

      ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Glenn C. Yiu, M.D., Ph.D., Professor of Ophthalmology at the University of California, Davis, to its Scientific Advisory Board (SAB), which is comprised of industry-leading retinal physicians who provide medical and scientific expertise and input on the Company's research and development programs. "We are privileged to welcome Dr. Yiu to our SAB, given his leadership in the research and adoption of new delivery approaches for t

      7/11/24 7:05:00 AM ET
      $CLSD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

      ALPHARETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Anthony S. Gibney has been appointed to the Company's Board of Directors, effective April 15, 2024. "We are delighted to welcome Tony to our Board of Directors as we build on our leadership in delivering therapeutics to the suprachoroidal space," said Clay Thorp, Chair of the Clearside Board of Directors. "We believe Tony's significant experience driving value for biotech companies through successful pipeline development, financing, partnerin

      4/16/24 7:05:00 AM ET
      $CLSD
      Biotechnology: Pharmaceutical Preparations
      Health Care